- Home
- JBI vs SYRE Comparison
JBI vs SYRE Comparison
Compare JBI & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBI
- SYRE
- Stock Information
- Founded
- JBI 2002
- SYRE 2013
- Country
- JBI United States
- SYRE United States
- Employees
- JBI N/A
- SYRE N/A
- Industry
- JBI Building Products
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- JBI Industrials
- SYRE Health Care
- Exchange
- JBI Nasdaq
- SYRE Nasdaq
- Market Cap
- JBI 1.2B
- SYRE 1.1B
- IPO Year
- JBI N/A
- SYRE 2016
- Fundamental
- Price
- JBI $10.07
- SYRE $23.15
- Analyst Decision
- JBI Buy
- SYRE Strong Buy
- Analyst Count
- JBI 4
- SYRE 6
- Target Price
- JBI $10.50
- SYRE $57.60
- AVG Volume (30 Days)
- JBI 671.3K
- SYRE 1.3M
- Earning Date
- JBI 11-06-2025
- SYRE 11-06-2025
- Dividend Yield
- JBI N/A
- SYRE N/A
- EPS Growth
- JBI N/A
- SYRE N/A
- EPS
- JBI 0.30
- SYRE N/A
- Revenue
- JBI $899,500,000.00
- SYRE N/A
- Revenue This Year
- JBI N/A
- SYRE N/A
- Revenue Next Year
- JBI $3.56
- SYRE N/A
- P/E Ratio
- JBI $32.32
- SYRE N/A
- Revenue Growth
- JBI N/A
- SYRE N/A
- 52 Week Low
- JBI $5.99
- SYRE $10.91
- 52 Week High
- JBI $10.80
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- JBI 53.97
- SYRE 72.26
- Support Level
- JBI $9.79
- SYRE $18.12
- Resistance Level
- JBI $10.20
- SYRE $23.49
- Average True Range (ATR)
- JBI 0.28
- SYRE 1.48
- MACD
- JBI 0.02
- SYRE 0.61
- Stochastic Oscillator
- JBI 82.78
- SYRE 95.54
About JBI Janus International Group Inc.
Janus International Group Inc is a manufacturer and supplier of turnkey solutions for self-storage, commercial, and industrial building Solutions. The company provides products that include roll-up and swing doors, hallway systems, relocatable storage MASS (Moveable Additional Storage Structures) units, and technologies for automating facility and door operation. It is operated through two geographic regions; Janus North America and Janus International. The Janus International segment is comprised of a subsidiary whose production and sales are largely in Europe and Australia. The Janus North America segment is comprised of all the other entities.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.